William Blair Has Strong Estimate for CRL FY2025 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Equities research analysts at William Blair upped their FY2025 earnings per share (EPS) estimates for Charles River Laboratories International in a research report issued to clients and investors on Thursday, August 7th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings per share of $10.29 for the year, up from their previous estimate of $9.79. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International's FY2026 earnings at $10.95 EPS.

CRL has been the subject of several other reports. Barclays raised their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 7th. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Wall Street Zen upgraded Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, Evercore ISI raised their price objective on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of "Hold" and a consensus price target of $175.69.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL traded up $2.05 during trading on Monday, hitting $157.85. The stock had a trading volume of 55,324 shares, compared to its average volume of 1,278,734. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $230.02. The stock has a market capitalization of $7.77 billion, a price-to-earnings ratio of -118.83, a price-to-earnings-growth ratio of 4.95 and a beta of 1.48. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The stock has a 50-day simple moving average of $156.63 and a two-hundred day simple moving average of $148.99.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.62. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%. The company's quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the company earned $2.80 earnings per share.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 400 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $150.04, for a total value of $60,016.00. Following the completion of the sale, the executive vice president directly owned 24,916 shares in the company, valued at $3,738,396.64. The trade was a 1.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.30% of the stock is owned by company insiders.

Institutional Trading of Charles River Laboratories International

A number of institutional investors and hedge funds have recently made changes to their positions in the business. EP Wealth Advisors LLC purchased a new stake in shares of Charles River Laboratories International in the second quarter valued at approximately $289,000. Brevan Howard Capital Management LP increased its position in shares of Charles River Laboratories International by 506.7% during the second quarter. Brevan Howard Capital Management LP now owns 33,544 shares of the medical research company's stock worth $5,090,000 after purchasing an additional 28,015 shares in the last quarter. Balyasny Asset Management L.P. increased its position in shares of Charles River Laboratories International by 722.5% during the second quarter. Balyasny Asset Management L.P. now owns 434,226 shares of the medical research company's stock worth $65,885,000 after purchasing an additional 381,432 shares in the last quarter. Bank of America Corp DE increased its position in shares of Charles River Laboratories International by 29.2% during the second quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company's stock worth $155,677,000 after purchasing an additional 232,020 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in shares of Charles River Laboratories International during the second quarter worth approximately $6,828,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).